Citigroup initiated coverage on NewAmsterdam Pharma with a new price target
$NAMS
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $42.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $52.00 | Buy | H.C. Wainwright |
| 8/25/2025 | $45.00 | Overweight | Wells Fargo |
| 7/17/2025 | $27.00 | Neutral | Goldman |
| 6/17/2025 | $42.00 | Buy | Citigroup |
| 6/10/2025 | $44.00 | Buy | Stifel |
| 6/4/2025 | $42.00 | Overweight | Cantor Fitzgerald |
| 12/30/2024 | $48.00 | Buy | H.C. Wainwright |
| 5/15/2024 | Buy | TD Cowen |
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00
Wells Fargo initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $45.00
Goldman initiated coverage of NewAmsterdam Pharma with a rating of Neutral and set a new price target of $27.00
NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial – overseeing all coronary plaque and inflammation measurements and monitoring. The REMBRANDT trial, sponsored by NewAmsterdam Phar
Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. "We appreciate the continued support of our limited partners, many of whom have been with us since the launch of o
NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the
SCHEDULE 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
SCHEDULE 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa
SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)